Exact Sciences (EXAS) will present three abstracts highlighting ... at the American Association for Cancer Research Special Conference in Cancer Research: Liquid Biopsy from November 13-16, 2024, in ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth quarter. The cut, which William Blair analysts called a “shocking ...

Exact Sciences stock collapsed Wednesday — undercutting its 50-day and 200-day lines — after the Cologuard maker reported ...

This article updates the investment merits of Exact Sciences following its disappointing Q3, 2024 earnings. Recent approval of an improved version of its lead product will not show up in revenues ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Jefferies analyst Tycho Peterson raised the firm’s price target on Exact Sciences (EXAS) to $85 from $84 and keeps a Buy rating on the shares. Q3 results “brought plenty of drama” with a 1% ...

Expanding Product Pipeline: Exact Sciences Corp's pipeline is rich with potential, including advancements in liquid biopsy tests for molecular residual disease (MRD), colorectal cancer screening, and ...